张琪琳，女，博士，副主任药师，硕士生导师。2015年毕业于华中科技大学药学院获博士学位，并于附属协和医院药学部工作至今。国家自然基金委通讯评审专家、教育部学位论文评审专家、中国医疗保险研究会药物经济专委会委员、湖北省药理学会治疗药物监测研究专委会委员、湖北省GCP检查员。《Glycoscience & Therapy》青年编委、《Infectious Medicine》青年编委。
研究方向
中药药理、药物安全性与经济性评价
研究及获奖情况
主持国家自然科学青年基金1项、省自然科学基金1项、湖北省卫健委面上项目1项、武汉市知识创新曙光计划项目1项、中国药学会优秀人才项目1项；参与国家重点研发计划、国家自然科学基金面上项目、湖北省中医药科研重点项目、药物临床试验等多项课题。以第一或通讯作者发表SCI论文30余篇，其中ESI高被引2篇，参与撰写并发布共识2部，授权发明专利2项。荣获湖北省科技进步一等奖1项（4/14）、《中国医院药学杂志》优秀论文一等奖、WILEY高被引论文作者奖。研发的医院新制剂“益肾排毒丸”成功获批湖北省医疗机构制剂注册批准文号（鄂药制字 Z20181033），并获医院新技术新业务成果奖三等奖。
一、主持科研项目：
1.湖北省卫生健康科技面上项目，WJ2025M193，基于RWD和决策分析的PARP抑制剂不良事件风险评估及卫生经济学评价研究，2025/07-2027/06，在研，主持
2.中国药学会医院药学专委会优秀人才项目，基于真实世界医疗大数据的抗银屑病生物制剂不良反应特征分析及其预测模型研究，2024/01-2025/12，在研，主持
3.武汉市知识创新专项曙光计划项目，基于真实世界医疗大数据的PARP抑制剂不良事件信号挖掘及其预测模型构建，2023/06-2025/06，已结题，主持
4. 国家自然科学青年基金，益肾排毒方抑制miR-21促进足细胞自噬治疗糖尿病肾病的作用机制研究，2022/01-2024/12，已结题，主持
5. 湖北省自然科学基金，当归多糖调节肝星状细胞活化增殖防治酒精性肝纤维化的作用及机制研究，2017/08-2019/07，已结题，主持
6. 湖北省生物靶向重点实验室，当归多糖靶向肝脏Nrf2-NF-κB通路抗APAP诱导的急性肝损伤的作用机制，2017/06-2019/06，已结题，主持
二、参与科研项目：
7. 国家自然科学基金，Dectin-1介导的香菇多糖体内吸收代谢机制研究，2020/01-2023/12，已结题，参与
8. 湖北省卫健委中医药科研重点项目，中药复方多糖胶囊剂的研发及其改善糖脂代谢的机制研究，2021/01-2022/12，已结题，参与
9. 国家重点研发计划项目子课题，典型病种精准用药模型的集成、推广与优化，2017/07-2020/12，已结题，参与
10. 国家自然科学基金，香菇多糖的抗肿瘤构效关系及诱导肿瘤细胞凋亡的分子机制研究，2014/01-2017/12，已结题，参与
三、论文代表作（第一作者或通讯作者）
1.Yamin Shu#, Ying Tang#, Yiling Ding, Wenting Zhang*, Qilin Zhang*. Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. Value in Health, 2026, S1098-3015(26)00076-8.
2.Yamin Shu#, Fenghao Shi#, Jinlin Xiong, Jienan Zheng, Yiling Ding, Wenting Zhang, Pingping Xu*, Qilin Zhang*. Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. iScience, 2026, 29(3): 114977.
3.Yamin Shu#, Shuhua Tan#, Yao Chen, Yiling Ding, Pingping Xu*, Qilin Zhang*. Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China. Infectious Medicine, 2026, 5(2): 100258.
4.Yiling Ding#, Zhen Wang#, Yamin Shu, Ying Tang*, Qilin Zhang*. Sorafenib-Related dermatologic toxicity: A Comprehensive Evaluation Based on Disproportionality Analysis and Clinical Characteristics. Dermatologic Therapy, 2025, 2025(1).
5.Lulu Liu#, Qilin Zhang#, Yamin Shu, Lei Wang, Zhenqingyun Shuai, Mingming Chu, Zhe Zhang*, Rong Zhang*. Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China. Pharmacoeconomics-Open, 2025, 9(6):887-902.
6.Yamin Shu#, Ying Tang#, Yiling Ding, Pingping Xu*, Qilin Zhang*. Cost-effectiveness of Sacituzumab Tirumotecan versus Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China. Breast, 2025, 83: 104550.
7.Lulu Liu#, Lei Wang#, Yiling Ding, Qilin Zhang*, Yamin Shu*. Cost-effectiveness of Atezolizumab plus Bevacizumab vs Sorafenib as First-Line Therapy in Unresectable Hepatocellular Carcinoma in the US and Chinese Setting: A Modelling Comparison Study. BMJ Open, 2025, 15: e094804.
8.Yiling Ding#, Chunping Wang#, Yamin Shu, Jinglin Wang*, Qilin Zhang*. Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial. Journal of Pharmaceutical Policy and Practice, 2025, 18(1): 2464781.
9.Yamin Shu#, Wenxin Cheng#, Xucheng He, Liu Huang, Wei Chen*, Qilin Zhang*. Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), Vaccine Adverse Event Reporting System, United States, October 2017-April 2024. Preventive Medicine Reports, 2025, 50: 102981.
10.Chen Shi#, Qilin Zhang#, Yufeng Li, Junjun Zhao, Cong Wang, Yu Zhang*. Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway. BMC Cardiovascular Disorders, 2024, 24(1):704.
11.Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu* and Qilin Zhang*. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis. Pharmaceuticals, 2024, 17(8):1028.
12.Qilin Zhang, Yiling Ding, Yamin Shu*, Jing Chen*. A Real-World Disproportionality Analysis of Rucaparib: Post-marketing Pharmacovigilance Data. BMC Cancer, 2023, 23(1):745.
13.Yamin Shu#, Lei Wang#, Yiling Ding, Qilin Zhang*. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment. Drug Safety, 2023, 46(9):881-895.
14.Yamin Shu#, Ying Tang#, Yufeng Ding, Qilin Zhang*. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. International Immunopharmacology, 2023, 122:110543.
15.Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang*. Adverse events with risankizumab in the real world: post-marketing pharmacovigilance assessment of the FDA adverse event reporting system. Frontiers in Immunology, 2023, 14:1169735.
16.Yamin Shu#, Yiling Ding#, Lulu Liu*, Qilin Zhang*. Cardiac Adverse Events Associated with Quetiapine: Disproportionality Analysis of FDA Adverse Event Reporting System. CNS Neuroscience & Therapeutics, 2023, 29(9):2705-2716.
17.Lulu Liu, Lei Wang, Li Chen, Yiling Ding, Qilin Zhang*, Yamin Shu*. Cost-effectiveness of Sintilimab Plus Chemotherapy versus Chemotherapy Alone as First-Line Treatment of Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma. Frontiers in Immunology, 2023, 14:1092385.
18.Yamin Shu#, Yiling Ding#, Feie Li*, Qilin Zhang*. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. International Immunopharmacology, 2023, 114:109589.
19.Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang*. Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Medicine, 2023, 12(3): 3365-3375.
20.Yamin Shu, Xucheng He, Pan Wu, Yanxin Liu, Yufeng Ding, Qilin Zhang*. Gastrointestinal Adverse Events Associated with Semaglutide: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. Frontiers in Public Health, 2022, 10:996179.
21.Ziming Zheng#, Qilin Zhang#, Yong Han, Tingting Wu*, Yu Zhang*. Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer. Cancer Control, 2022, 29:1-10.
22.Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang*. Cost-effectiveness of Osimertinib versus Standard EGFR-TKI as First-line Treatment for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer in China. Frontiers in Pharmacology, 2022, 13:920479.
23.Yamin Shu#, Qilin Zhang#, Xucheng He, Yanxin Liu, Pan Wu, Li Chen*. Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on FAERS database. Frontiers in Pharmacology, 2022, 13:990241.
24.Yamin Shu, Yanxin Liu, Xucheng He, Yufeng Ding, Qilin Zhang*. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. Frontiers in Pharmacology, 2022, 13:818579.
25.Yamin Shu, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang*. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Clinical Epidemiology, 2022, 14:789-802.
26.Yamin Shu#, Yufeng Ding#, Yanxin Liu, Pan Wu, Xucheng He, Qilin Zhang*. Post-marketing Safety Concerns with Secukinumab: A Disproportionality Analysis of FDA Adverse Event Reporting System. Frontiers in Pharmacology, 2022, 13:862508.
27.Yamin Shu, Yufeng Ding, Qilin Zhang*. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China. Frontiers in Oncology, 2022, 12:851522.
28.Yamin Shu, Yufeng Ding, Bing Dai, Qilin Zhang*. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opinion on Drug Safety, 2022, 21(4): 563-572.
29.Qilin Zhang#, Tingting Wu#, Yong Han, Zi-ming Zheng*, Yu Zhang*. Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management. Current Medical Science, 2022, 42(3):530-537.
30.Qilin Zhang, Pan Wu, Xucheng He, Yufeng Ding, Yamin Shu*. Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers in Oncology, 2021, 11:790373.
31.Yu Zhang, Yufeng Li, Junjun Zhao, Cong Wang, Bin Deng, Qilin Zhang*, Chen Shi*. Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice. Frontiers in Pharmacology, 2021, 12:781856.
32.Qilin Zhang#, Xiaocui Liu#, Mitchell A. Sullivan, Chen Shi*, Bin Deng*. Protective Effect of Yi Shen Pai Du Formula against Diabetic Kidney Injury via Inhibition of Oxidative Stress, Inflammation, and Epithelial-to-Mesenchymal Transition in db/db Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021:7958021.
33.Qilin Zhang, Ziming Zheng*, Yu Zhang*. Association of Myocardial Enzyme Abnormality with Clinical Outcomes of Patients with COVID-19: A Retrospective Study. Disease Markers. 2021, 2021:3440714.
34.Yaming Shu#, Qilin Zhang#, Xucheng He, Li Chen*. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China. Cancer Management and Research. 2021, 13:8297-8306.
35.Qilin Zhang, Zhaosong Du, Yu Zhang, Ziming Zheng, Qiang Li, Kaiping Wang*. Apoptosis induction activity of polysaccharide from Lentinus edodes in H22-bearing mice through ROS-mediated mitochondrial pathway and inhibition of tubulin polymerization. Food & Nutrition Research, 2020, 64, 1-13.
36.张琪琳，陈力，戴冰，舒亚民*. 基于FAERS对帕博利珠单抗和纳武利尤单抗不良事件的分析. 中国药师, 2022, 25(8): 1384-1390.
37.张琪琳，陈力，舒亚民*. 基于FAERS数据库的芳香化酶抑制剂不良事件信号挖掘研究. 中国现代应用药学, 2022, 40(2): 224-231.
38.张琪琳，戴冰，舒亚民*. 培美曲塞联合贝伐珠单抗维持治疗晚期非鳞状非小细胞肺癌成本-效果分析. 中国药业, 2022, 31(10): 106-111.
39.张琪琳，秦琰杰，戴冰，舒亚民*. 聚乙二醇脂质体阿霉素联合化疗方案治疗复发性卵巢癌的成本-效果分析. 中国医院药学杂志，2021, 41(22):2322-2327.
40.张琪琳，刘小翠，刘亚鸽，于丽秀，邓斌*. 益肾排毒丸调节AMPK/ACC信号通路对db/db小鼠肝损伤的保护作用研究. 中国医院药学杂志，2021,41(4):360-366.
41.张琪琳，舒亚民，潘祥林，张玉*，王凯平*. 药食同源植物多糖治疗溃疡性结肠炎的药理作用及机制研究进展. 药物评价研究，2021,44(3):644-651.
42.邓斌, 王秋燕, 周成高, 张琪琳*. 益肾排毒丸中有效成分含量测定及指纹图谱研究. 药物评价研究, 2019, 42(4): 658-662.
43.刘小翠, 邓斌, 张琪琳*. 益肾排毒丸的稳定性研究. 中国医药导报, 2019, 16(13): 29-32.
44.张琪琳, 邓斌*, 周成高, 王秋燕. 益肾排毒丸的薄层鉴别及急性毒性试验. 中国药师, 2019, 22(8): 1523-1526.
45.张琪琳，杜兆松，王凯平，张玉*，香菇多糖抑制Akt通路和微管蛋白聚合诱导肿瘤细胞凋亡的分子机制，中国医院药学杂志，2016, 36(23):2046-2051.
联系方式：027-85726073 E-mail:qilinzhang88@163.com
通讯地址：华中科技大学同济医学院附属协和医院 邮政编码 430022
